Medical Department, Panyu Maternal and Children Healthcare Hospital (Hexian Memorial Medical Hospital of Panyu District), Guangdong, China.
Imaging Department, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, China.
Future Oncol. 2024;20(38):3141-3149. doi: 10.1080/14796694.2024.2402215. Epub 2024 Oct 7.
The effect of skeletal muscle mass and density on the long-term survival outcome of breast cancer patients is unclear. Systematically searched all articles in PubMed, Web of science, Springerlink, EMBASE and Wiley databases that studied the association between skeletal muscle and survival outcomes of breast cancer by 25 September 2023. The hazard ratios and confidence intervals of the multiple factor analysis results controlling for confounding variables in the study were collected and analyzed using STATA 14.0 software. This meta-analysis included a total of 13 studies, with a median age of 48.2 years. Meta results showed that the survival (hazard ratio [HR]: 0.98, 95% CI: 0.89-1.08) and recurrence (HR: 0.96, 95% CI: 0.92-1.00) outcomes of breast cancer patients with sarcopenia were not significantly affected compared with those without sarcopenia. No significant heterogeneity or publication bias was observed in the study. The conclusion that skeletal muscle is regarded as a useful factor that can guide and optimize the prognosis of breast cancer patients is uncertain, or the result is very weak. Considering the impact of research quality and confounding factors, prospective studies are needed in the future to further demonstrate.PROSPERO identifier: CRD42023463480 (www.crd.york.ac.uk/prospero).
骨骼肌质量和密度对乳腺癌患者长期生存结局的影响尚不清楚。系统检索了 2023 年 9 月 25 日之前在 PubMed、Web of science、Springerlink、EMBASE 和 Wiley 数据库中所有研究骨骼肌与乳腺癌生存结局之间关系的文章。使用 STATA 14.0 软件收集并分析了研究中控制混杂因素的多因素分析结果的风险比和置信区间。这项荟萃分析共纳入 13 项研究,中位年龄为 48.2 岁。荟萃分析结果表明,与非肌肉减少症患者相比,肌肉减少症乳腺癌患者的生存(风险比 [HR]:0.98,95%CI:0.89-1.08)和复发(HR:0.96,95%CI:0.92-1.00)结局无显著影响。研究未观察到明显的异质性或发表偏倚。骨骼肌被认为是指导和优化乳腺癌患者预后的有用因素的结论不确定,或者结果非常微弱。考虑到研究质量和混杂因素的影响,未来需要进行前瞻性研究以进一步证实。PROSPERO 标识符:CRD42023463480(www.crd.york.ac.uk/prospero)。